First Horizon Advisors’s Viking Therapeutics VKTX Stock Holding History

First Horizon Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$21.5K	Buy	813 +458	+129%	+$12.1K	﹤0.01%	1392
2025 Q1	$8.57K	Sell	355 -7	-2%	-$221	﹤0.01%	1661
2024 Q4	$14.6K	Buy	362 +41	+13%	+$2.34K	﹤0.01%	1454
2024 Q3	$20.3K	Buy	321 +212	+194%	+$12.4K	﹤0.01%	1349
2024 Q2	$5.78K	Buy	109 +25	+30%	+$1.64K	﹤0.01%	1719
2024 Q1	$6.89K	Buy	+84	New	+$3.74K	﹤0.01%	1724
2021 Q4	–	Sell	-811	Closed	-$4K	–	2446
2021 Q3	$4K	Hold	811	–	–	﹤0.01%	1811
2021 Q2	$4K	Hold	811	–	–	﹤0.01%	1600
2021 Q1	$4K	Hold	811	–	–	﹤0.01%	1527
2020 Q4	$4K	Hold	811	–	–	﹤0.01%	1255
2020 Q3	$4K	Hold	811	–	–	﹤0.01%	1220
2020 Q2	$5K	Hold	811	–	–	﹤0.01%	1181
2020 Q1	$3K	Hold	811	–	–	﹤0.01%	1214
2019 Q4	$6K	Hold	811	–	–	﹤0.01%	1237
2019 Q3	$5K	Hold	811	–	–	﹤0.01%	1257
2019 Q2	$6K	Hold	811	–	–	﹤0.01%	1242
2019 Q1	$7K	Hold	811	–	–	﹤0.01%	1170
2018 Q4	$5K	Buy	+811	New	+$9.7K	﹤0.01%	1249

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

First Horizon Advisors's VKTX Position: Q2 2025 in Review

First Horizon Advisors increased its Viking Therapeutics (VKTX) stake by 129% in Q2 2025, buying an estimated $12.1K and bringing the position to 813 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

First Horizon Advisors first reported a position in VKTX in Q4 2018 and has held it in 18 quarters since. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

First Horizon Advisors held 813 shares of Viking Therapeutics worth $21.5K as of Q2 2025.
First Horizon Advisors bought 458 Viking Therapeutics shares in Q2 2025, an estimated $12.1K.
Viking Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1392 holding.
First Horizon Advisors first reported a position in Viking Therapeutics in Q4 2018 and has held it in 18 quarters since.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.